华昊中天医药-B(02563)今日在港交所挂牌上市,开盘一度大涨34.38%,报21.5港元,成交额2245.05万港元,引发了市场的广泛关注。
作为一家合成生物学技术驱动的生物医药公司,华昊中天医药专注于开发肿瘤创新药物,已成功开发出三大核心技术平台,拥有一种国产一类创新药"优替德隆注射液"已获批上市,并有19种其他管线抗癌候选药物正处于临床试验阶段。
此次华昊中天医药-B的上市获得超高认购,公开发售部分认购达21.45倍,国际发售部分也获0.994倍超额认购,最终采用下限发行价16港元。分析人士表示,这表明投资者对该公司的发展前景非常看好。该公司2022-2023年期间营收和毛利增长也超过95%,展现出良好的经营状况和增长动能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.